GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prescient Therapeutics Ltd (ASX:PTX) » Definitions » 5-Year RORE %

Prescient Therapeutics (ASX:PTX) 5-Year RORE % : -4.44% (As of Dec. 2023)


View and export this data going back to 1986. Start your Free Trial

What is Prescient Therapeutics 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Prescient Therapeutics's 5-Year RORE % for the quarter that ended in Dec. 2023 was -4.44%.

The industry rank for Prescient Therapeutics's 5-Year RORE % or its related term are showing as below:

ASX:PTX's 5-Year RORE % is ranked better than
54.02% of 1057 companies
in the Biotechnology industry
Industry Median: -7.16 vs ASX:PTX: -4.44

Prescient Therapeutics 5-Year RORE % Historical Data

The historical data trend for Prescient Therapeutics's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prescient Therapeutics 5-Year RORE % Chart

Prescient Therapeutics Annual Data
Trend Jun13 Jun14 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
5-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -18.84 -9.09 -9.80 -12.77

Prescient Therapeutics Semi-Annual Data
Dec13 Jun14 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.26 -9.80 -12.24 -12.77 -4.44

Competitive Comparison of Prescient Therapeutics's 5-Year RORE %

For the Biotechnology subindustry, Prescient Therapeutics's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prescient Therapeutics's 5-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prescient Therapeutics's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where Prescient Therapeutics's 5-Year RORE % falls into.



Prescient Therapeutics 5-Year RORE % Calculation

Prescient Therapeutics's 5-Year RORE % for the quarter that ended in Dec. 2023 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( -0.01--0.012 )/( -0.045-0 )
=0.002/-0.045
=-4.44 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2023 and 5-year before.


Prescient Therapeutics  (ASX:PTX) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Prescient Therapeutics 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of Prescient Therapeutics's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Prescient Therapeutics (ASX:PTX) Business Description

Traded in Other Exchanges
N/A
Address
Level 4, 100 Albert Road, South Melbourne, Melbourne, VIC, AUS, 3205
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.

Prescient Therapeutics (ASX:PTX) Headlines

No Headlines